Dr. Gus Alva on an Effective Therapy for Elderly Patients With Neurodegenerative Diseases
By Dr. Gus Alva, Rob Dillard - Last Updated: August 20, 2024A recent study, published in the Journal of Alzheimer’s Disease, evaluated the safety of pimavanserin compared with placebo in frail older adult and elderly patients with neuropsychiatric symptoms related to neurodegenerative diseases, such as hallucinations and delusions.
Advertisement
To learn more about the significance of the findings, DocWire News spoke with Gus Alva, MD, founder and medical director of ATP Clinical Research, a premier private clinical research company focused on new treatments for a variety of neuropsychiatric conditions.
Advertisement
Related Posts
Dr. Anne Marie Morse discusses the troubling connection between sleep disorders and dementia.
The caps on the end of chromosomes are called telomeres.
A new model called the Florey Dementia Index (FDI) can accurately predict the age at onset of MCI and AD.
The research group will design a vaccine that won't promote inflammation.
The phase 2 randomized trial included patients with amyloid-confirmed mild cognitive impairment or early Alzheimer disease.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.